Nevertheless, not all patients exhibit favorable responses, and the currently available biomarkers (such as PDL1 expression, tumor-infiltrating lymphocytes, and tumor mutational burden) do not consistently provide reliable predictions of treatment outcomes. Here, CD274 is linked to neoplasm.